Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atrium Therapeutics, Inc. - Common Stock (NQ:RNA)

12.17 -0.10 (-0.81%)
Streaming Delayed Price Updated: 2:26 PM EDT, Aug 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 28,783
Open 12.27
Bid (Size) 12.13 (100)
Ask (Size) 12.15 (600)
Prev. Close 12.27
Today's Range 12.06 - 12.35
52wk Range 11.13 - 73.06
Shares Outstanding 54,462,518
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Sarepta's RNA Renaissance: 35% Surge as siRNA Breakthrough Silences Skeptics
CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ: SRPT) skyrocketed 35% in early trading today, reaching levels not seen since the company’s early days in Duchenne Muscular... 
Via MarketMinute
Top movers in Friday's after hours session ↗
Via Chartmill

Performance

YTD
-83.1%
-83.1%
1 Month
-0.4%
-0.4%
3 Month
-7.4%
-7.4%
6 Month
-83.3%
-83.3%
1 Year
-73.4%
-73.4%

More News

Read More
News headline image
The Era of the Titans: Q4 2025 Mega-Deal Surge and the 2026 Economic Map
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Halper Sadeh LLC Encourages TWO, RNA, CVBF, TBN Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market
Via MarketMinute
Topics Artificial Intelligence ETFs Initial Public Offering
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
Via MarketMinute
Topics ETFs Intellectual Property
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
Via The Motley Fool
Topics Lawsuit Regulatory Compliance
News headline image
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
Via The Motley Fool
Topics Lawsuit Regulatory Compliance
News headline image
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Halper Sadeh LLC Encourages WTRG, RNA, TCBX Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts ↗
Via Benzinga
News headline image
Here's How Much $100 Invested In Avidity Biosciences 5 Years Ago Would Be Worth Today ↗
Via Benzinga
News headline image
Looking Into Avidity Biosciences Inc's Recent Short Interest ↗
Via Benzinga
News headline image
Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Essential Utilities, Inc. (NYSE – WTRG), Cadence Bank (NYSE – CADE), Avidity Biosciences, Inc. (Nasdaq – RNA), Plymouth Industrial REIT, Inc. (NYSE – PLYM)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) ↗
Via The Motley Fool
News headline image
Unusual volume stocks in Thursday's session ↗
Via Chartmill
News headline image
$1000 Invested In Avidity Biosciences 5 Years Ago Would Be Worth This Much Today ↗
Via Benzinga
News headline image
RNA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Avidity Biosciences, Inc. is Fair to Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Nucor To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Via Benzinga
News headline image
This Boot Barn Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
Via Benzinga

Frequently Asked Questions

Is Atrium Therapeutics, Inc. - Common Stock publicly traded?
Yes, Atrium Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Atrium Therapeutics, Inc. - Common Stock trade on?
Atrium Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Atrium Therapeutics, Inc. - Common Stock?
The ticker symbol for Atrium Therapeutics, Inc. - Common Stock is RNA on the Nasdaq Stock Market
What is the current price of Atrium Therapeutics, Inc. - Common Stock?
The current price of Atrium Therapeutics, Inc. - Common Stock is 12.17
When was Atrium Therapeutics, Inc. - Common Stock last traded?
The last trade of Atrium Therapeutics, Inc. - Common Stock was at 08/12/26 02:26 PM ET
What is the market capitalization of Atrium Therapeutics, Inc. - Common Stock?
The market capitalization of Atrium Therapeutics, Inc. - Common Stock is 662.81M
How many shares of Atrium Therapeutics, Inc. - Common Stock are outstanding?
Atrium Therapeutics, Inc. - Common Stock has 663M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.